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Abstract 
Non-enzymic glycosylation (glycation) of structural proteins has been widely studied as a possible mechanism in the long-term 
complications of diabetes. Here we show that glycation inactivates malate dehydrogenase. Aspirin affords some protection against he 
glycation, but a-crystallin, a lens protein which appears to act as a molecular chaperone in other systems, is much more effective. For 
example, 5 mM glucose completely inactivates malate dehydrogenase in four days, and 5 /xg a-crystallin/ml provides complete 
protection against his inactivation. Fructose, a superior glycating agent, inactivates the enzyme in 24 hours but even so the same low 
concentration of a-crystallin is able to protect 80% of the activity. Other proteins provide no protection at the same concentration. The 
inactivation of malate dehydrogenase and other enzymes by glycation could play a role in diabetic complications, and molecular 
chaperones like a-crystallin could serve to protect hem. 
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1. Introduction 
Diabetes is associated with a number of long-term 
complications including neuropathy, retinopathy, cataract, 
nephropathy and angiopathy. For example diabetic patients 
are four to six times more likely to develop cataract 
compared with non-diabetics [1]. 
One suggested mechanism for the formation of cataract 
and other complications in diabetes is the non-enzymic 
binding of sugars with proteins; this is a condensation 
reaction between the carbonyl group of the sugar and free 
amino groups at the NH2-terminus or E-amino groups of 
lysine residues of the proteins. The product of this reaction 
is a Schiff base, which is then converted to the more stable 
Amadori product [2]. Reaction of carbonyl groups on these 
Amadori products results in the formation of intermolecu- 
lar cross-links which lead to the formation of high-molecu- 
lar weight aggregates that scatter light [3,4]. Haemoglobin 
was the first protein shown to be glycated in vivo; glyca- 
tion shifts the haemoglobin-oxygen dissociation curve, 
which could compromise oxygen delivery to the cells [5,6]. 
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The ligand binding properties of albumin are also altered 
by glycation [7]. 
The lens is insulin-independent and therefore the intra- 
cellular glucose concentration reflects that of the extracel- 
lular environment [8]. A possible consequence of this 
increase in glucose in the lens is greater glycation of the 
lens proteins. The concentrations of other sugars in the 
lens are also increased in diabetes [9]. Glucose 6-phosphate 
(G6P) has been found to cause conformational changes by 
non-enzymic reactions with a- and 7-crystallins [2,10]. 
Fructose, galactose and glucosamine, a metabolite of glu- 
cose, all cause structural changes of lens proteins through 
reaction with their amino groups [11-13]. A number of 
studies investigating lycation of structural proteins have 
been carried out, but this has not been done to the same 
degree for glycation of enzymes. Enzymes play a vital role 
in the body and any change to their activity, structure or 
affinity for substrate could have profound effects on their 
efficiency. The enzymes RNase [14], liver glucokinase 
[ 15], /3-galactosidose, alkaline phosphatase [ 16], glucose- 
6-phosphate dehydrogenase [17], and Cu-Zn-superoxide 
dismutase [ 18-21 ] are inactivated by glycation. Glycation 
also alters the kinetics of Na--,K+-ATPase [22]. In this 
study we examined the effect of glycation on malate 
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dehydrogenase, an enzyme with an important role in en- 
ergy provision. 
Proteins in the centre of the lens, unlike other proteins, 
are not turned over [23]. This could result in the accumula- 
tion of modified proteins over a very long period of time, 
resulting in the loss of structural integrity of the lens; 
which in turn would affect its ability to focus light on the 
retina. Transparency of the lens is maintained by the short 
range order of the lens proteins as has been shown by 
phase separation experiments [24]. 
Aspirin, paracetamol and ibuprofen protect against 
cataract development in diabetic rats [25]; and are associ- 
ated with a protective ffect against cataract in man [26,27]. 
In vitro aspirin and other analgesics protect against lens 
opacification [28,29]. Aspirin and ibuprofen also display 
an in vitro protective ffect against he non-enzymic modi- 
fication of lens proteins [29], and protect against glycation 
of lens proteins by glucosamine [13], galactose [12,29], 
glucose and fructose [11]. Apart from the effects on glyca- 
tion, aspirin has also been shown to decrease the incidence 
of stroke and myocardial infarction [30]. 
The major lens protein, ce-crystallin, is able to suppress 
thermally induced aggregation of enzymes, and of /3- and 
y-crystallins [31,32]. The molecular chaperone GroEL has 
also shown this ability to suppress thermally induced 
aggregation of enzymes; the kinetic behaviour of the c~- 
crystallin system being very similar to that of GroEL. 
Previous studies have shown that the amino-acid sequence 
of c~-crystallin is homologous to the small heat-shock 
proteins (hsps) [33]. Mouse hsp 25 and a-crystallin share 
other structural characteristics and can form mixed aggre- 
gates providing more evidence that c~-crystallin may have 
functions in the lens additional to that of its refractive 
function; c~-crystallin may function as a molecular chaper- 
one in the lens preventing the aggregation of enzymes and 
other crystallins. Very recently we showed that c~-crystal- 
lin could protect glucose-6-phosphate dehydrogenase 
against glycation-induced inactivation [17]. 
In the present work we investigated whether the glu- 
cose, fructose and glucose 6-phosphate (G6P) used had 
any adverse affects on the activity of MDH. We then 
determined whether either aspirin or ibuprofen were able 
to exert a protective ffect against any inhibitory action of 
the sugars. We then studied the protective properties of 
c~-crystallin in this system and compared it with four 
protein standards, human albumin, bovine serum albumin, 
egg albumin and lysozyme, to help in determining whether 
c~-crystallin can be classified as a molecular chaperone. 
2. Materials and methods 
2.1. Materials 
Porcine heart malate dehydrogenase was obtained from 
Sigma Chemicals (Poole, Dorset, UK). All other chemicals 
were obtained from either Sigma or BDH (Lutterworth, 
Leics., UK). Bovine lenses were obtained from the local 
slaughterhouse. 
2.2. Malate dehydrogenase assay 
The enzyme activity of porcine heart malate dehydro- 
genase (MDH) was determined by monitoring the decrease 
in absorption at 340 nm as oxaloacetate was reduced by 
NADH, using a Kontron 930 spectrophotometer. The en- 
zyme was prepared in 0.02 ml of 0.05 M potassium 
phosphate buffer (pH 7.5) incubated in the spectrophotom- 
eter at 37°C in a quartz cuvette with 2.85 ml of the above 
buffer and 0.1 ml of 15 mM oxaloacetate for 1 rain, before 
the addition of 0.03 ml of 12 mM NADH. The mixture 
was stirred rapidly and the decrease in absorption was 
monitored over 1.5 min against a water blank. 
2.3. Incubation with sugars 
To determine whether fructose, glucose and G6P had an 
affect on MDH activity, the incubation solution above was 
incubated with these sugars, (which were dissolved in 0.05 
M sodium phosphate buffer (pH 7.0) to a final concentra- 
tion of 5 mM). Stock solutions of the incubation solution 
with and without the sugars were made, and divided up 
into small separate sterilized glass vials (3 vials per stock 
solution) with rubber tops through a sterilized 0.2 /~m- 
pore-size Millipore filter. The vials were placed in a 
shaking water bath at 37°C. Zero-time readings were taken 
in triplicate, and samples were taken from the set of three 
vials per stock experiment and assayed at 2, 4, 6, 8, 24 h, 
and then every day for 4 days. The graphs are produced 
from a minimum of three values per point. 
2.4. Protective effect of aspirin / ibuprofen against sugar 
inhibition 
Both aspirin and ibuprofen were dissolved in the 0.05 
M sodium phosphate buffer (pH 7.0) and incorporated into 
the incubation solution with or without sugars (5 mM). 
Aspirin concentrations of 10 and 20 mM and an ibuprofen 
concentration of 10 mM were used. Incubation and assay 
of enzyme activity was as described above. 
2.5. Isolation and purification of bot,ine lens o~-c~, stallin 
Lenses were removed from fresh bovine eyes and stored 
at -20°C. Five lenses (approx. 1.95 g per lens) were 
thawed, decapsulated and homogenized with elution buffer 
(0.05 M sodium phosphate, 0.2 M KCI, 1 mM EDTA, 1 
mM EGTA; pH 6.7). The mixture was then centrifuged at 
12 000 × g for 20 min. 
The lens structural proteins, crystallins, were separated 
by gel chromatography on Sephacryl 300HR by the method 
of Slingsby and Bateman [34]. The supernatant was loaded 
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onto a 980 by 75 mm column packed with Sephacryl 
300HR eluted at a flow rate of 100 ml/h.  The eluent was 
collected in 10 ml aliquots, fractions were taken and read 
at 280 nm. 
The peaks that came off the column were separately 
pooled, the first being a-crystallin, and were dialyzed until 
there was no salt present in the surrounding water. The 
dialyzed protein was freeze-dried and stored at -20°C. 
SDS-PAGE was performed on the pooled fraction, show- 
ing that a-crystallin is free from contamination by the 
other crystallins (results not shown). 
2.6. Protective effect of  a-crystallin against sugar inhibi- 
tion 
The a-crystallin, isolated as described above was dis- 
solved in 0.05 M sodium phosphate buffer (pH 7.0) and 
added to the enzyme solution to give a final concentration 
of 0.005 mg/ml  and 0.5 mg/ml  in the incubation solu- 
tion, with or without sugar. Incubation and assay of en- 
zymic activities was as described above. To further investi- 
gate the protective properties of a-crystaltin, several pro- 
tein standards were also used. Human serum albumin and 
bovine serum albumin have lysine contents double that of 
a-crystallin [35-37], whereas those of egg albumin and 
lysozyme are similar to a-crystallin [38,39]. The concen- 
trations of standards used were 0.005 mg/ml  and 0.05 
mg/ml.  
2.7. Incorporation of  radio-labelled fructose into lysozyme, 
bovine serum albumin, and a-crystallin 
Each protein (100 mg) was incubated in 5 mM fructose 
(containing 10 /zCi [14C]fructose) in 100 mM sodium 
phosphate (pH 7.4) at 37°C for up to 6 h (total volume 10 
ml). Aliquots (0.5 ml in quadruplicate) were removed at 1, 
3, and 6 h. They were deproteinized using 1 ml 15% 
trichloroacetic acid. Bovine serum albumin (5 /zl of 5 
mg/ml  solution) was added to aid precipitation which 
proceeded for 18 h at 4°C. The precipitates were collected 
on fibre glass filters, dried and radioactivity measured on a 
scintillation counter [40]. 
(p  < 0.01), whereas glucose took much longer; the en- 
zyme activity being reduced by 53% + 9.7% after 2 days 
(p  < 0.01) (Fig. 2). 
3.2. Incubations with aspirin and ibuprofen 
The incorporation of 10 mM aspirin into the incubation 
assay did not provide any protection against he inactiva- 
tion of MDH by glycation by fructose, both incubations 
with and without aspirin inactivated MDH to the same 
extent (98 _+ 0.23% inactivation after 24 h) (Fig. 3). Incu- 
bations with 10 mM aspirin and G6P indicated that the 
aspirin was having a slight protective affect against glyca- 
tion by G6P; after 24 h there was 85% _+ 9.4% (p  < 0.001, 
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Fig. 1. inhibition of MDH by 5 mM fructose and 5 mM glucose 
6-phosphate (G6P). 
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Fig. 2. Inhibition of MDH by 5 mM glucose. 
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3. Results 
3.1. Incubations with 5 mM sugar solutions 
None of the sugars inhibited malate dehydrogenase at 
zero time but fructose, G6P and glucose all inactivated the 
enzyme with time. The degree of inactivation and the time 
taken for inactivation varied between the sugars. Fructose 
was the most effective taking only 2 h to inactivate MDH 
by 38.5% +_ 8.3% (p < 0.01, Student t-test), and 4 h to 
inactivate by 68.5% + 7.9% (p < 0.001) (Fig. 1). G6P 
reduced the activity of MDH by 41%_+ 7.4% in 6 h 
120 
~E 100 
o k 
o 
Z" 60 ~ 
.~. 
o 4(? o 
10 20 30 
Period of Incubotion (Hours) 
Fig. 3. Protective effect of i0 mM aspirin against inactivation fMDH by 
G6P and fructose. 
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Fig. 4. Protective ffect of 10 mM aspirin against inactivation of MDH by 
5 mM glucosc. 
comparing inactivation without aspirin) inactivation of 
MDH, with aspirin present, as opposed to 98 + 0.8% 
inactivation in incubations with G6P without aspirin (Fig. 
3). 
The effect of 10 mM aspirin on the glycation of MDH 
by glucose was more pronounced; after 4 days MDH had 
been inactivated by 64.5% _ 0.5% (p = 0.002) (Fig. 4), in 
comparison to the inactivation of 95.3% +_ 4% seen in 
incubations without aspirin. 
Increasing the concentration of aspirin to 20 mM failed 
to provide any protection against inactivation of MDH by 
fructose; there was 99 + 0.2% inactivation after 24 h. No 
additional protection was provided by 20 mM aspirin 
against inactivation of MDH by G6P; the level of inactiva- 
tion remaining at around 85 _+ 0.2% (p  < 0.001). Increas- 
ing the concentration of aspirin to 20 mM in incubations 
with glucose and MDH increased its protective effect; 
there was 51.5 + 0.5% (p  < 0.01) inactivation of the MDH 
by glucose after 4 days (results not shown), in comparison 
to the inactivation of 64.5 + 0.5% with 10 mM aspirin. 
No protection against glycation by fructose, G6P or 
glucose was seen by 10 mM ibuprofen (data not shown). 
3.3. Incubation with a-crvstallin 
a-Crystallin was isolated by gel chromatography (Fig. 
5) and was introduced into the incubation vials at two 
concentrations; 0.005 mg/ml  (ratio of MDH: a-crystallin, 
1:40) and 0.5 mg/ml  (MDH:a, 1:4000). Four protein 
standards at 0.005 and 0.05 mg/ml  concentration were 
also run in order to investigate whether the protective role 
of this lens protein was unique. 
No protection was provided by the albumins at 0.005 
mg/ml  and by lysozyme at either 0.005 or 0.5 mg/ml  
(Fig. 6). Protection against inactivation of MDH by 5 mM 
fructose was afforded by all three albumins at 0.5 mg/ml ,  
over 8 h incubation (Fig. 6b). There was 72.6_+ 2.9% 
inactivation of MDH in the presence of human albumin 
(HA), p = 0.005; 64.7 _+ 3.4%, inactivation in the pres- 
ence of bovine serum albumin (BSA), p < 0.001 and 
84 + 0,5%, inactivation in the presence of egg albumin 
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Fig. 5. Elution profile of bovine lens crystallins on Sephacryl 300 HR 
(980×75 mm) eluted at 100 ml/h. The first peak was pooled as 
a-crystallin. 
(EA), p < 0.001 (all t-test values compared to inactivation 
by fructose only). This result could be explained by the 
fact that albumins contain a relatively large amount of 
lysine residues on their surface which are available for 
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Fig. 7. Protection provided by 0.005 mg a-crystallin per ml against 
inactivation fMDH by 5 mM fructose and G6P. 
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Fig. 10. Protective effect of 0.5 mg a-crystallin per ml against glucose- 
induced inactivation fMDH. 
glycation by fructose; lysozyme, in comparison contains 
fewer lysines and therefore glycation by fructose is less 
likely to occur. The glycation of these proteins could 
protect MDH from complete inactivation by glycation. 
However, in the incubation with 0.005 mg/ml  protein 
standards, the inactivation of MDH increases and the 
enzyme is inactivated to the same extent as the incubations 
with fructose only (Fig. 6a). The proteins at this concentra- 
tion may no longer be able to protect against he inactiva- 
tion of MDH. At the higher concentration of protein 
standards protection is afforded by the albumins through- 
out the 8 h incubation, this is not seen with lysozyme (Fig. 
6b). 
The lens protein a-crystallin, at a concentration of 
0.005 mg/ml ,  seemed to protect against glycation of 
MDH by all three sugars (Figs. 7 and 8). The greatest 
protection was afforded against inactivation by glucose 
where MDH had 91.5% ± 3.8% (p < 0.001) of the activ- 
ity of the control after 4 days (Fig. 8); protection against 
O6P and fructose was very similar to that of glucose, 
MDH having 87.7% + 10.6% (p<0.001)  and 77%+ 
15.8% (p < 0.001) of the activity of the control respec- 
tively after 24 h (Fig. 7). Increasing the concentration of 
a-crystallin to 0.5 mg/ml  resulted in complete protection 
against glycation by all three sugars, (p  < 0.001) _ 0.5% 
(Figs. 9 and 10). The results with a-crystallin, which has a 
comparatively ow lysine content compared to the albu- 
mins and the lack of a free N-terminal a-amino group 
(unlike in the protein standards), could indicate another 
mechanism for protection against glycation other than its 
own glycation ahead of that of MDH. 
At the lower concentration it is unlikely that a-crystal- 
lin is simply competing for the fructose because it lacks 
the a-amino group which is usually more reactive with 
sugars and it has fewer lysine residues than the control 
proteins. Nevertheless we checked on the reactivity of 
these proteins with radiolabelled fructose (Fig. 11). Bovine 
serum albumin, lysozyme and a-crystallin all bind fructose 
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Fig. 11. Glycation of BSA, lysozyme and a-crystallin by radiolabelled 
fructose. 
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at a similar rate. a-Crystallin was not significantly more 
reactive although it was by far the most effective in 
protecting MDH (Figs. 6-8). In fact at the end of the six 
hour incubation no more than 0.03% of the fructose was 
bound to any of the proteins so they cannot be lowering 
the effective concentration of fructose available for glyca- 
tion. 
The protective effect of a-crystallin in this system 
appears to be specific when compared to the other proteins 
supporting the view that it has chaperone-like properties. 
4. Discussion 
Glycation affects many proteins and is of most interest 
in diabetes, where excess glycation of many proteins in- 
cluding haemoglobin, albumin, collagen and lens crys- 
taltins has been found [41]. 
The time-dependent i activation of MDH by fructose, 
G6P and glucose suggests that these sugars bind non-en- 
zymically to the enzyme; an explanation for the implica- 
tion of these glycating agents in the formation of cataracts 
could come from the fact that some of them are metabolic 
intermediates, and are present in the lens in significant 
concentrations that increase in diabetes [23]. We used a 
concentration of sugar (5 mM) that lay within the physio- 
logical range of sugar levels in the diabetic lens; the 
concentration of fructose within the diabetic lens is be- 
tween 1.2 and 12 mM and that of glucose is between 3 and 
4.5 mM [42]; the concentration of G6P has also been 
shown to increase in the diabetic lens [9]. The rate of 
glycation is dependent on the percentage of sugar in the 
open chain form; the carbonyl group is then available for 
forming a Schiff-base. Fructose, which has a greater eac- 
tivity with haemoglobin, has a higher percentage in the 
open chain form than glucose, 0.7% for fructose and 
0.002% for glucose [43]. This could explain the more rapid 
inhibition of MDH activity by fructose, as the first stage in 
the Maillard reaction is a nucleophilic attack by the amino 
group of the protein on the carbonyl group of the sugar; 
this reaction can only take place when the sugar is in the 
open chain form. G6P also inhibited MDH activity more 
rapidly than glucose. This could be due to the phosphate 
group increasing the level of disruption of the enzyme 
through an increase in surface negative charge; this idea 
has been suggested for the unfolding of y-crystallin by 
G6P [10]. Near ultra-violet circular dichroism spectra per- 
formed in the same paper, indicate that G6P binding to 
lens proteins resulted in an alteration in the isoelectric 
point and tertiary/quarternary structure of the protein. The 
reactivity of the sugar is not solely dependent on the 
carbonyl content; the position of any phosphate groups 
present also seems to be an important factor in the reactiv- 
ity of the sugar [44]. 
Glycation occurs by reaction of sugars with free amino 
groups of lysine residues. Malate dehydrogenase has 87 
lysine residues/1000 residues [45] as potential glycation 
sites. Over half of the lysine residues are found within 
c~-helices, and some are involved in hydrogen bonding and 
the structural stability of the catalytic domain of this 
globular dimer; 8 of the lysines are in /3-sheet formation, a
number of which are part of the NAD binding domain, 
which takes up the first 153 residues. Work carried out on 
haemoglobin has suggested that it is the higher order 
structure (tertiary/quarternary) of the protein that deter- 
mines the Amadori rearrangement activity of the glycation 
sites, rather than the amino-acid sequence around the 
non-enzymic glycation site [46]. In vivo glycation of free 
amino groups of glutathione reductase indicates that there 
is a preference for lysyl-lysine sequences as opposed to 
single lysine residues [47]. The concentration of reduced 
glutathione decreases with cataract [23]; this reducing agent 
being used to diminish the opacification of a protein 
solution treated with hexose [2]. The decrease in GSH 
correlates with the increased opacification in diabetic rats 
[48]. Glutathione reductase maintains the level of GSH in 
the cell, it has a lysyl-lysine pair in its catalytic centre. 
Glycation of this pair could contribute to a decrease in 
enzyme activity, seen in human cataracts, and hence a 
lowering of the level of GSH in early diabetic cataract 
[48]. Porcine cytoplasmic malate dehydrogenase has a 
lysyl-lysine present at the surface of the protein at posi- 
tions 120 and 121 [45], and is in an optimum position for 
being attacked by sugar; this could lead to disruption of 
the dimer through the prevention of NAD binding and 
hence a reduction in enzymic activity. The binding of G6P 
could additionally exert electrostatic repulsion which could 
disrupt hydrogen bonding and the integrity of the dimer. 
These glycation studies indicate that sugars bind to 
enzymes and other proteins in tissues exposed to sugars 
leading to unfolding inactivation and aggregation. Most of 
the work on glycation has been done on structural proteins, 
however, alterations in enzyme activity as a result of 
glycation have been shown. Incubations of three enzymes; 
/3-galactosidase, alkaline phosphatase and G6P dehydro- 
genase with glucose over a period of 6 days demonstrated 
an increase in K m for all three enzymes after glucosyla- 
tion and competitive inhibition of /3-galactosidase was 
induced by glucosylation [ 16]. Glycation studies in the past 
have focused on the glucosylation of lens proteins as a 
cause of diabetic ataracts. The discovery that fructose and 
G6P are more reactive than glucose regarding interaction 
with lens proteins and enzymes, implies that they may play 
an important role in the development of diabetic cataracts 
particularly as fructose is present at a higher concentration 
than glucose in diabetic human lenses [42]. Fructose is 
often recommended as a substitute for sucrose for diabet- 
ics, and many diabetic foods contain fructose. In the light 
of the results obtained for the fructosylation of lens pro- 
teins and enzymes, diabetic foods containing fructose could 
be having a detrimental effect on the patient. 
If glycation of enzymes and proteins is important in the 
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aetiology of cataract and other tissue damage, measures 
that prevent he reaction may prevent he tissue damage. 
Aspirin has a protective ffect against glycosylation by 
galactose [12] and glucosamine [13]. The mechanism of 
protection is believed to be acetylation, as work on the 
prevention of non-enzymic arbamylation of proteins by 
aspirin indicated that acetylation was important in the 
protective ffect [28]. Work on protection against glyco- 
sylation by glucosamine [ 13] provides further evidence that 
it is acetylation that protects the proteins; protection against 
glucosamine was afforded by aspirin (acetysalicyclic a id) 
but not by salicyclic acid, which is structurally identical 
except for the absence of the acetyl group. The acetylation 
by aspirin of amino groups of a variety of proteins has 
been seen, including haemoglobin, albumin and immuno- 
globulins [41]. 
Incubation of aspirin with the sugars and MDH resulted 
in aspirin displaying protection against glycation by glu- 
cose and to a lesser degree against glycation by G6P. 
Aspirin, at concentrations of 10 and 20 mM was unable to 
prevent glycation of MDH by fructose. Fructose inacti- 
vates MDH much more quickly than glucose; fructose 
reducing the enzyme's activity to 65.5% of the control in 2 
hours, glucose taking 2 days to reduce the activity to 47%. 
Aspirin's inability to protect against glycation by fructose 
could be a result of the fast rate of reaction between 
fructose and MDH; in the experiments with glucose aspirin 
has more time to react with MDH as glucose is slower at 
glycating the enzyme. 
Acetylation may not be the only mechanism for protec- 
tion against glycation of proteins. The analgesic ibuprofen, 
unlike aspirin, does not have an acetyl group. Ibuprofen, 
however, has been shown to protect against cataract in 
epidemiological studies [27] and in the diabetic rat [25], 
where it decreased the amount of glycation. It protected 
against glycation of bovine lens proteins by glucosamine 
[13] and fructose [11]. Ibuprofen (10 mM) did not afford 
any protection of MDH against glycation by any of the 
three sugars used. Binding studies were performed be- 
tween lens proteins and ibuprofen, to examine the mecha- 
nism of the protective action against cataract but only 
weak binding could be demonstrated [49]. There must be 
another mechanism whereby ibuprofen protects against 
cataract. This weak binding cannot account for the thera- 
peutic effect of the drug; as in order to protect he proteins, 
the drug must be able to stay on the protein molecule 
tightly enough to compete with any cataractogenic agents 
for binding sites. It is possible that cataract may be pre- 
vented not through ibuprofen itself, but through a metabo- 
lite of ibuprofen which might have an additional 
hydrogen-bonding species; this metabolite could be pro- 
duced elsewhere in the body and then travel to the lens. 
Thus the two anti-inflammatory drugs have rather limited 
benefits especially when it is recalled that the concentra- 
tions used were greatly in excess of levels achieved in 
tissues during treatment. 
a-Crystallin is affected by non-enzymic chemical modi- 
fication by sugars and other substances, e.g. cyanate; but 
there is now growing evidence that a-crystallin itself can 
provide protection against modification of proteins. The 
work performed so far has examined the protective ffect 
a-crystallin has on heat-induced aggregation of its fellow 
lens crystallins and various enzymes [3 i ,32]. Horwitz found 
no effect on enzyme inactivation. The in vitro work per- 
formed here, investigated the possibility that a-crystallin 
could prevent he reduction in activity of MDH caused by 
glycation - -  a more gradual process than thermal denatu- 
ration. A similar protection has been found for glucose-6- 
phosphase dehydrogenase [17]. 
We found that at low concentrations (0.005 mg/ml) 
a-crystallin seemed to provide protection against inactiva- 
tion of MDH by all three sugars, the greatest protection 
being afforded against inactivation by glucose. When the 
concentration f a-crystallin was increased to 0.5 mg/ml, 
the lens protein provided complete protection against he 
inactivation of MDH. The possibility that this protection 
could be solely due to the sugars glycating a-crystallin 
rather than MDH can probably be discounted from the 
results of the experiments with the protein standards and 
the fact that MDH has nearly twice as many lysine residues 
per 1000 residues as a-crystallin [50,51] and so do some 
of the control proteins. 
The results of the glycation experiments with the pro- 
tein standards was that even the lysine-rich plasma albu- 
min was unable to protect MDH from glycation, despite 
having over twice the number of lysine residues when 
compared to a-crystallin. This therefore indicates that 
there is a specific protective role for a-crystallin and its 
role may be in the form of a molecular chaperone. The 
effect of a-crystallin is all the more striking when the 
lower concentration used (0.005 mg/ml) is compared with 
the concentration i vivo, which can be 160 mg/ml in 
bovine lens and only slightly less in human lens. 
One of the functions of the proteins ynthesized by cells 
in response to heat shock, is to minimize the denaturing 
effects of heat shock upon the native structure of the 
proteins [52]. It appears that these heat-shock proteins 
(hsps) preferentially bind to partially denatured forms of 
polypeptides, this protects them from further denaturation 
and aggregation and may enable a more rapid renaturation 
of the denatured protein. The changes resulting from heat- 
induced denaturation could also occur as a result of other 
chemical changes, e.g., osmolarity changes and post-trans- 
lational modification (e.g., glycation); these processes have 
been implicated in complications of diabetes including 
cataractogenesis. There is no turnover of proteins in the 
centre of the lens, making them very susceptible to any 
modifications known to occur in vivo [23]. It is therefore 
possible that the lens contains proteins with a similar role 
to the hsps. 
There are sequence similarities between hsp 27 in 
Drosophila and mammalian a-A and a-B crystaltins [33]. 
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Anfinsen's basic idea that all the information eeded for 
protein folding is held in the amino-acid sequence still 
holds true in principle. In vitro, some isolated proteins can 
be denatured and refolded, usually very slowly, in the 
absence of other macromolecular cellular components; in
vivo, however, the folding and assembly of polypeptides 
requires other proteins known as molecular chaperones 
[53]. Their function is thought o be to temporarily stabi- 
lize unfolded or partially folded structures and to keep 
them in a form that will enable them to subsequently fold 
and assemble. The main role of molecular chaperones 
appears to be to prevent he incorrect intermolecular sso- 
ciation of unfolded polypeptide chains, which would result 
in their aggregation. Two distinct mechanisms of chaper- 
one action have evolved; the first is to prevent aggregation 
by the shielding of hydrophobic surfaces, this is carried out 
by the Hsp 70 family of chaperones; Dna K, Dna J and 
GrpE. The second mechanism involves the removal of a 
complete but as yet unfolded protein from the cellular 
environment to prevent aggregation, and simultaneously 
allow folding to the native state to proceed; this is per- 
formed by the Hsp 60 family of chaperones, GroEL and 
GroES. These two mechanisms can act together in a 
sequential pathway of folding [53]. 
Work carried out on the possible chaperone properties 
of o~-crystallin have shown that it is able to protect against 
thermal aggregation of enzymes, e.g., the rate and amount 
of aggregation of yeast c~-glucosidase was reduced on 
titration with bovine a-crystallin [32]. a-Crystallin also 
had a similar effect on enolase, glutathione-S-transferase, 
alcohol dehydrogenase, carbonic anhydrase, lactate dehy- 
drogenase, aldolase and phosphoglucose isomerase, a- 
Crystallin also suppressed the aggregation of /3H-crystallin 
and of bovine y-crystallin [32]. The addition of an equimo- 
lar concentration of o~-crystallin to a denatured sample of 
ys-crystallin resulted in 95% of the original sample being 
recovered; ce-crystallin therefore aiding the refolding of the 
denatured Ys. 
In the central region of the mammalian lens (the lens 
nucleus) there is no detectable protein synthesis and yet 
there are measurable activities of a variety of enzymes 
[23]. It is often pointed out that the enzyme activity here is 
less than in the outer part of the lens (the cortex) but it was 
difficult to explain how there could be any activity in cells 
that had not synthesized protein for decades. The demon- 
stration that ce-crystallin can act as a molecular chaperone 
provides an explanation for this enigma. Thirty or 40% of 
lens protein is oL-crystallin. Lens enzymes are more heav- 
ily chaperoned than those in any other tissue. 
oz-Crystallin is a very good example of gene sharing, 
where a protein has two functions in a certain tissue. 
a-Crystallin is expressed at high levels in the lens where it 
contributes to the refractive properties and serves as a 
molecular chaperone, protecting enzymes and other pro- 
teins in the lens against aggregation that will lead to light 
scattering and loss of function. The fact that ce-crystallin 
appears to protect lens proteins from denaturation and light 
scattering, leads to the proposal that the age-related deteri- 
oration of c~-crystallin may have a major role in the onset 
of cataract. Any post-translational modifications that occur 
with age - -  e.g., glycation - -  may interfere with the 
chaperone function of a-crystallin and lead to its aggrega- 
tion and aggregation of other crystallins. 
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